secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K/A
Filed at:   2026-06-18T20:04:56+00:00
Accession:  0001628280-26-044260
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion acquires Corstasis for $83.4M, financed via $25M loan and $50M royalty sale
--------------------------------------------------------------------------------

- Total acquisition cost $83.4M: $77.5M cash to Corstasis plus $5.9M direct transaction costs.
- Acquired developed product intangible Enbumyst valued at $77.1M, amortized over 10 years.
- Financing: $25M term loan at 9.75% (effective ~10.5%) and $50M royalty sale to Athyrium with $100M cap.
- Pro forma net loss for 2025 increases to $47.1M from $22.7M historical; no goodwill recognized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026044260/0001628280-26-044260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026044260/espr-20260402.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-044260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer